Philadelphia, PA – March 1, 2022 – Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative nervous therapies for central system (CNS) disorders, today announced the opening of its application process for its inaugural Tachi Yamada Scholarship program.
The new scholarship program is for junior students enrolled in life science programs at four-year colleges and universities in Pennsylvania and who plan to have a career in the life sciences industry. Passage Bio will select one sophomore student annually to award $10,000 in scholarship funding – $5,000 over two years to be used toward college-related expenses. Interested sophomore students have until April 1, 2022, to apply for the program’s first scholarship.
Passage Bio first announced its plans to launch the annual Tachi Yamada Scholarship Program in October 2021 to continue the legacy of Tadataka (Tachi) Yamada, MD, a visionary biopharma industry leader who passed away in August 2021. Yamada was a co-founder of Passage Bio and served as chairman of the company’s board of directors until his sudden passing. He had a life-long devotion to mentoring and building the next generation of scientists.
“We could not think of a better way to honor Tachi’s legacy than by supporting and nurturing budding scientists who are the future of our industry,” said Bruce Goldsmith, Ph.D., chief executive officer and president, Passage Bio. “We also believe in supporting our community, and this scholarship program is an important way for our company, which is based in Philadelphia, to aid the continued growth and development of life sciences in Pennsylvania.”
In addition to the financial award, the selected scholar will be matched with a Passage Bio mentoring for professional growth opportunities over the two-year scholarship period.
To apply, students must be sophomores, who will be juniors in the fall of 2022, attending four-year colleges or universities in Pennsylvania and majoring in a life science discipline. They must have a cumulative unweighted grade average point of 3.0 and be a United States citizen or permanent resident of the United States or hold a US student visa. The student must also write a 500-word essay as part of the application process. The official rules are available with the online application, and the application is due April 1. You can also access the application from Passage Bio’s website in the Careers section at Passage Bio, Inc. – Careers. All applications will be evaluated by a panel of Passage Bio employees and the winner will be selected by Passage Bio at its discretion.
About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming genetic medicines for patients with CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.
For further information, please contact: